youtube_live
Q3 2026 earnings • released • EPS beat +27.23% • Revenue beat +128.58%
See resultschevron_right
EDIT:NASDAQ
Editas Medicine Inc
US$2.93
arrow_upward
+14.01%(+0.36) 1D
ኖቬም 9, 1:52:14 ከሰዓት ጂ ኤም ቲ-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
US$2.64
High
US$2.94
Low
US$2.51
Mkt. cap
449.99 ሚ
Avg. vol.
2.28 ሚ
Volume
1.58 ሚ
52-wk high
US$3.94
52-wk low
US$1.66
EPS
-US$0.74
Beta
2.09
Shares outstanding
153.58 ሚ
No. of employees
87
Open
US$2.64
High
US$2.94
Low
US$2.51
Mkt. cap
449.99 ሚ
Avg. vol.
2.28 ሚ
Volume
1.58 ሚ
52-wk high
US$3.94
52-wk low
US$1.66
EPS
-US$0.74
Beta
2.09
Shares outstanding
153.58 ሚ
No. of employees
87
News stories
From web sources and news partners
TradingView
·
ከ4 ሰዓቶች በፊት
Editas Medicine, Inc. reports results for the quarter ended September 30 - Earnings Summary
Zacks
·
ከ5 ሰዓቶች በፊት
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Investing.com
·
ከ5 ሰዓቶች በፊት
Editas Medicine earnings beat by $0.04, revenue topped estimates
Yahoo Finance
·
ከ6 ሰዓቶች በፊት
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
Foundedኖቬም 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com